{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:00:48Z","timestamp":1787061648949,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Corrona, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-017-1496-5","type":"journal-article","created":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T20:32:52Z","timestamp":1514838772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry"],"prefix":"10.1186","volume":"20","author":[{"given":"Leslie R.","family":"Harrold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Litman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly J.","family":"Dandreo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Suruki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari","family":"Jaganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"issue":"2 Suppl 1","key":"1496_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422001-00002","volume":"22","author":"TK Kvien","year":"2004","unstructured":"Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 Suppl 1):1\u201312.","journal-title":"Pharmacoeconomics"},{"issue":"9746","key":"1496_CR2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094\u2013108.","journal-title":"Lancet"},{"issue":"12","key":"1496_CR3","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","volume":"59","author":"JA Avina-Zubieta","year":"2008","unstructured":"Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690\u20137.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1496_CR4","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287\u201393.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1496_CR5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.berh.2007.05.003","volume":"21","author":"SM Naz","year":"2007","unstructured":"Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):871\u201383.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"1496_CR6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1496_CR7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","volume":"63","author":"C Barnabe","year":"2011","unstructured":"Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4):522\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"1496_CR8","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"DH Solomon","year":"2015","unstructured":"Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449\u201355.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1496_CR9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53\u201361.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1496_CR10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","volume":"66","author":"J Askling","year":"2007","unstructured":"Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66(10):1339\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"1496_CR11","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275\u201385.","journal-title":"JAMA"},{"issue":"9","key":"1496_CR12","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56(9):2896\u2013904.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1496_CR13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124\u201331.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1496_CR14","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","volume":"68","author":"JP Leombruno","year":"2009","unstructured":"Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68(7):1136\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1496_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1496_CR16","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","volume":"56","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor \u03b1 therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(6):1754\u201364.","journal-title":"Arthritis Rheum"},{"issue":"9990","key":"1496_CR17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258\u201365.","journal-title":"Lancet"},{"key":"1496_CR18","first-page":"CD012183","volume":"5","author":"JA Singh","year":"2016","unstructured":"Singh JA, Hossain A, Tanjong Ghogomu E, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016;5:CD012183.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"1496_CR19","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1496_CR20","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","volume":"63","author":"AE Thompson","year":"2011","unstructured":"Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2011;63(6):1479\u201385.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1496_CR21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","volume":"54","author":"F Wolfe","year":"2006","unstructured":"Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628\u201334.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1496_CR22","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","volume":"64","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64(10):1421\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1496_CR23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","volume":"68","author":"T Bongartz","year":"2009","unstructured":"Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009;68(7):1177\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1496_CR24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis. 2013;72(4):517\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1496_CR25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10067-011-1895-y","volume":"31","author":"AK Wong","year":"2012","unstructured":"Wong AK, Kerkoutian S, Said J, et al. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol. 2012;31(4):631\u20136.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1496_CR26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/sim.4780100409","volume":"10","author":"H Petri","year":"1991","unstructured":"Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10(4):577\u201381.","journal-title":"Stat Med"},{"key":"1496_CR27","unstructured":"FDA. Cimzia (certolizumab pegol) Prescribing Information; last updated April 2016. Available at: \nhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125160s241lbl.pdf\n\n. Last accessed: September 2016."},{"issue":"5 Suppl 39","key":"1496_CR28","first-page":"S172","volume":"23","author":"JM Kremer","year":"2005","unstructured":"Kremer JM. The CORRONA database. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S172\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"1496_CR29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2474-13-85","volume":"13","author":"MC Fisher","year":"2012","unstructured":"Fisher MC, Furer V, Hochberg MC, et al. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord. 2012;13:85.","journal-title":"BMC Musculoskelet Disord"},{"issue":"11","key":"1496_CR30","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/ard.2009.122226","volume":"69","author":"DH Solomon","year":"2010","unstructured":"Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010;69(11):1920\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1496_CR31","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/rheumatology\/kep205","volume":"48","author":"JR Curtis","year":"2009","unstructured":"Curtis JR, Patkar NM, Jain A, et al. Validity of physician-reported hospitalized infections in a US arthritis registry. Rheumatology (Oxford). 2009;48(10):1269\u201372.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1496_CR32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"10061","key":"1496_CR33","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Burmester GR, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388(10061):2763\u201374.","journal-title":"Lancet"},{"issue":"5","key":"1496_CR34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1496_CR35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/ard.2010.146365","volume":"70","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Xie F, Chen L, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011;70(8):1401\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1496_CR36","first-page":"653","volume":"32","author":"P Emery","year":"2014","unstructured":"Emery P, Gallo G, Boyd H, et al. Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2014;32(5):653\u201360.","journal-title":"Clin Exp Rheumatol"},{"issue":"21","key":"1496_CR37","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","volume":"306","author":"CG Grijalva","year":"2011","unstructured":"Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306(21):2331\u20139.","journal-title":"JAMA"},{"issue":"8","key":"1496_CR38","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3899\/jrheum.121288","volume":"40","author":"A Weaver","year":"2013","unstructured":"Weaver A, Troum O, Hooper M, et al. Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1. J Rheumatol. 2013;40(8):1275\u201381.","journal-title":"J Rheumatol"},{"issue":"1","key":"1496_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges Jr SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"1496_CR40","first-page":"CD008794","volume":"2","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"1496_CR41","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1136\/ard.2008.102103","volume":"68","author":"GR Burmester","year":"2009","unstructured":"Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68(12):1863\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1496_CR42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol. 2016;68(1):56\u201366.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1496_CR43","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","volume":"55","author":"L Silva-Fern\u00e1ndez","year":"2016","unstructured":"Silva-Fern\u00e1ndez L, Lunt M, Kearsley-Fleet L, et al. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology (Oxford). 2016;55(11):2033\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1496_CR44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/ket333","volume":"53","author":"CL Morgan","year":"2014","unstructured":"Morgan CL, Emery P, Porter D, et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford). 2014;53(1):186\u201394.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1496_CR45","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","volume":"60","author":"J Askling","year":"2009","unstructured":"Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor \u03b1 therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009;60(11):3180\u20139.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1496_CR46","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","volume":"71","author":"LK Mercer","year":"2012","unstructured":"Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2012;71(6):869\u201374.","journal-title":"Ann Rheum Dis"},{"key":"1496_CR47","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","volume":"346","author":"P Raaschou","year":"2013","unstructured":"Raaschou P, Simard JF, Holmqvist M, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013;346:f1939.","journal-title":"BMJ"},{"key":"1496_CR48","first-page":"w14290","volume":"146","author":"C Turesson","year":"2016","unstructured":"Turesson C. Comorbidity in rheumatoid arthritis. Swiss Med Wkly. 2016;146:w14290.","journal-title":"Swiss Med Wkly"},{"issue":"7","key":"1496_CR49","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.11078","volume":"48","author":"I Rincon Del","year":"2003","unstructured":"Del Rincon I, Williams K, Stern MP, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum. 2003;48(7):1833\u201340.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1496_CR50","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1496_CR51","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00296-014-2945-y","volume":"34","author":"T Cobo-Ibanez","year":"2014","unstructured":"Cobo-Ibanez T, Descalzo MA, Loza-Santamaria E, et al. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int. 2014;34(7):953\u201361.","journal-title":"Rheumatol Int"},{"issue":"3","key":"1496_CR52","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1496_CR53","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","volume":"74","author":"VP Bykerk","year":"2015","unstructured":"Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74(1):96\u2013103.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1496_CR54","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/acr.22377","volume":"66","author":"JR Curtis","year":"2014","unstructured":"Curtis JR, Chen L, Bharat A, et al. Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken). 2014;66(12):1790\u20138.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1496-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T16:10:57Z","timestamp":1589818257000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1496-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,2]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1496-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,2]]},"article-number":"2"}}